Marileila Varella-Garcia

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. pmc Chromosomal and genomic changes in lung cancer
    Marileila Varella-Garcia
    Departments of Medicine and Pathology, University of Colorado Denver, Anschutz Medical Center, University of Colorado Cancer Center, Aurora, CO, USA
    Cell Adh Migr 4:100-6. 2010
  2. pmc The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence
    Marileila Varella-Garcia
    University of Colorado Denver, 12801 East 17th Avenue, Aurora, CO 80045, USA
    Cancer Prev Res (Phila) 3:447-53. 2010
  3. pmc Biologic and genetics aspects of chagas disease at endemic areas
    Marilanda Ferreira Bellini
    Department of Especial Education, UNESP Sao Paulo State University, 17525 900 Campus Marília, SP, Brazil
    J Trop Med 2012:357948. 2012
  4. doi request reprint ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers
    Dara L Aisner
    University of Colorado School of Medicine Anschutz Medical Campus, 12801 East 17th Avenue, L18 8118, Mail Stop 8117, Aurora, CO 80045
    Mol Cancer Res 12:111-8. 2014
  5. pmc EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer
    M Varella-Garcia
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    J Clin Pathol 62:970-7. 2009
  6. ncbi request reprint Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Federico Cappuzzo
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA
    J Natl Cancer Inst 97:643-55. 2005
  7. ncbi request reprint Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study
    Fred R Hirsch
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Clin Oncol 23:6838-45. 2005
  8. pmc Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression
    Rafal Dziadziuszko
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 28:2174-80. 2010
  9. ncbi request reprint Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 24:5034-42. 2006
  10. pmc Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012

Detail Information

Publications53

  1. pmc Chromosomal and genomic changes in lung cancer
    Marileila Varella-Garcia
    Departments of Medicine and Pathology, University of Colorado Denver, Anschutz Medical Center, University of Colorado Cancer Center, Aurora, CO, USA
    Cell Adh Migr 4:100-6. 2010
    ..Additionally, this knowledge has supported the development of novel therapeutics and translational tools for selection of patients for personalized therapy...
  2. pmc The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence
    Marileila Varella-Garcia
    University of Colorado Denver, 12801 East 17th Avenue, Aurora, CO 80045, USA
    Cancer Prev Res (Phila) 3:447-53. 2010
    ..The apparent promise of CA-FISH in sputum for assessing lung cancer risk and/or for lung cancer early detection now needs to be validated in a clinical screening trial...
  3. pmc Biologic and genetics aspects of chagas disease at endemic areas
    Marilanda Ferreira Bellini
    Department of Especial Education, UNESP Sao Paulo State University, 17525 900 Campus Marília, SP, Brazil
    J Trop Med 2012:357948. 2012
    ..However, Chagas disease is still active, and aspects such as host-parasite interactions, genetic mechanisms of cellular interaction, genetic variability, and tropism need further investigations in the attempt to eradicate the disease...
  4. doi request reprint ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers
    Dara L Aisner
    University of Colorado School of Medicine Anschutz Medical Campus, 12801 East 17th Avenue, L18 8118, Mail Stop 8117, Aurora, CO 80045
    Mol Cancer Res 12:111-8. 2014
    ..Implications: ROS1 and ALK fusions occur in colorectal cancer and may have substantial impact in therapy selection...
  5. pmc EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer
    M Varella-Garcia
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    J Clin Pathol 62:970-7. 2009
    ..This article discusses the consensus outcomes of a global workshop convened to discuss key technical issues and standardise reading strategies for the EGFR FISH assay of NSCLC tumour tissue...
  6. ncbi request reprint Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Federico Cappuzzo
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA
    J Natl Cancer Inst 97:643-55. 2005
    ..We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC...
  7. ncbi request reprint Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study
    Fred R Hirsch
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Clin Oncol 23:6838-45. 2005
    ..Epidermal growth factor receptor (EGFR) inhibitors demonstrated response rates of 20% to 30% in patients with advanced BAC subtypes, but selection methods for patient therapy are not established...
  8. pmc Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression
    Rafal Dziadziuszko
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 28:2174-80. 2010
    ....
  9. ncbi request reprint Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
    J Clin Oncol 24:5034-42. 2006
    ..We analyzed ISEL tumor biopsy samples to examine relationships between biomarkers and clinical outcome after gefitinib treatment in a placebo-controlled setting...
  10. pmc Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
    Robert C Doebele
    Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4502-11. 2012
    ..It is hypothesized that the dominant oncogene in NSCLC would be associated with distinct patterns of metastatic spread in NSCLC at the time of diagnosis...
  11. pmc Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development
    Todd M Pitts
    Division of Medical Oncology, University of Colorado Denver, Aurora, CO 80045, USA
    Clin Cancer Res 16:3193-204. 2010
    ..The goal of this study was to develop and characterize predictive biomarkers for an IGFIR tyrosine kinase inhibitor, OSI-906, that could be applied in CRC-specific studies of this agent...
  12. ncbi request reprint Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer
    Rafal Dziadziuszko
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Clin Cancer Res 12:3078-84. 2006
    ....
  13. pmc Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer
    D Ross Camidge
    University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA
    Cancer 118:4486-94. 2012
    ..Increased copy numbers of fused and rearranged signals also occur. Here, correlations are explored between the percentage of ALK+ cells and signal copy number and their association with response to ALK inhibition...
  14. pmc EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort
    Marileila Varella-Garcia
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80045, USA
    J Thorac Oncol 4:318-25. 2009
    ..This study was carried out to verify whether EGFR FISH had similar performance in Japanese patients...
  15. doi request reprint First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado, Health Sciences Center, Aurora, CO, USA
    J Thorac Oncol 3:S138-42. 2008
    ....
  16. pmc Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:6317-23. 2008
    ..Here, we assess the value of using epidermal growth factor receptor (EGFR) gene copy number in tumor biopsy samples, as determined by fluorescence in situ hybridization (FISH), as a predictor of treatment outcome...
  17. pmc Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer
    Steinn Jonsson
    Department of Medicine Medical Oncology, University of Colorado Health Sciences Center, Campus Box 6511, Mail Box 8117, Aurora, CO 80045, USA
    Am J Respir Crit Care Med 177:342-7. 2008
    ..The development of lung cancer (LC) is accompanied by field changes in the airway mucosa that may have prognostic importance...
  18. ncbi request reprint Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels
    Barbara A Helfrich
    Tobacco Related Malignancy Program, University of Colorado Cancer Center, Aurora, CO 80010, USA
    Clin Cancer Res 12:7117-25. 2006
    ..Downstream cell cycle and signaling events were compared with growth-inhibitory effects...
  19. ncbi request reprint Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report
    Rafal Dziadziuszko
    Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
    J Thorac Oncol 2:91-2. 2007
    ..Molecular characterization of the primary tumor before any treatment is provided, and mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors are briefly discussed...
  20. pmc Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
    D Ross Camidge
    Department of Medical Oncology, University of Colorado Denver, 1665 North Ursula Street, Room 2256, P O Box 6510, Mail Stop F 706, Aurora, CO 80045 0508, USA
    J Thorac Oncol 6:774-80. 2011
    ..To explore whether the progression-free survival (PFS) with pemetrexed differs between anaplastic lymphoma kinase (ALK)-positive and other major molecular subtypes of non-small cell lung cancer...
  21. ncbi request reprint Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Paul A Bunn
    Department of Medicine, University of Colorado Cancer Center and University of Colorado Health Sciences Center, Aurora, 80045, USA
    Clin Cancer Res 12:3652-6. 2006
  22. pmc ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer
    John J Arcaroli
    Division of Medical Oncology, University of Colorado Denver and University of Colorado Cancer Center, Aurora, CO 80045, USA
    Mol Oncol 6:370-81. 2012
    ..These results indicate the combination of PF-03084014 and irinotecan may be effective in reducing tumor recurrence in CRC patients whose tumors exhibit elevated levels of the Notch pathway...
  23. pmc Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib
    John J Arcaroli
    Division of Medical Oncology, University of Colorado Denver and University of Colorado Cancer Center, Denver, Colorado 80045, USA
    Clin Cancer Res 18:2704-14. 2012
    ..Because these pathways appear to enhance tumor growth and metastasis, molecularly targeted agents for both pathways are currently being evaluated in early-phase clinical trials...
  24. ncbi request reprint Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies
    Fred R Hirsch
    University of Colorado Cancer Center, Departments of Medicine Medical Oncology and Pathology, Denver, CO 80262, USA
    Lung Cancer 41:S29-42. 2003
    ..Gene amplification for EGFR and HER2 is demonstrated in only 5-10% of the tumors. The treatment status and therapeutic limitation with trastuzumab (Herceptin) in lung cancer compared to breast cancer is discussed...
  25. pmc Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models
    Jennifer R Diamond
    Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Cancer Res 19:291-303. 2013
    ..The purpose of this study was to evaluate the antitumor activity of the Aurora and angiogenic kinase inhibitor ENMD-2076 against preclinical models of breast cancer with identification of candidate predictive biomarkers...
  26. pmc Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
    Kurtis D Davies
    Division of Medical Oncology, University of Colorado, MS 8117, 12801 E 17th Ave, Aurora, CO 80045, USA
    Clin Cancer Res 18:4570-9. 2012
    ..In this study, we sought to characterize ROS1 fusion genes in non-small cell lung cancer (NSCLC) and establish the fusion proteins as drug targets...
  27. doi request reprint Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy
    Samir E Witta
    University of Colorado Cancer Center, 12801 E 17th Ave, Mail Stop 8117, Aurora, CO 80045, USA
    J Clin Oncol 30:2248-55. 2012
    ..This randomized phase II study evaluated the outcome of erlotinib with and without the isoform selective HDACi, entinostat...
  28. pmc A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
    Fred R Hirsch
    University of Colorado Cancer Center, 12801 E 17th Ave, Aurora, CO 80045, USA
    J Clin Oncol 29:3567-73. 2011
    ....
  29. pmc The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas
    Ryan T Anderson
    Corresponding Author Antonio Jimeno, University of Colorado School of Medicine, MS8117, 12801 East 17th Avenue, Room L18 8101B, Aurora, CO 80045
    Mol Cancer Ther 12:1994-2005. 2013
    ..Although consistent inhibition of the PI3K pathway was not evident in HNSCC, we identified a combination of PI3K/TP53 events necessary, but not sufficient, for rigosertib sensitivity...
  30. pmc Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
    Robert C Doebele
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80209, USA
    Clin Cancer Res 18:1472-82. 2012
    ..This study aimed to define molecular mechanisms of resistance to crizotinib in patients with ALK(+) non-small cell lung cancer (NSCLC)...
  31. pmc Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models
    Todd M Pitts
    Division of Medical Oncology, University of Colorado Anschutz Medical Campus Aurora, CO, USA
    Front Pharmacol 4:35. 2013
    ..These results indicate that PAK inhibition is associated with a unique response phenotype in CRC and that further studies should be conducted to facilitate both patient selection and rational combination strategies with these agents...
  32. ncbi request reprint Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
    Federico Cappuzzo
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80010, USA
    J Clin Oncol 23:5007-18. 2005
    ..Preclinical data indicate that HER2, a member of the EGFR family, could enhance TKI sensitivity...
  33. pmc Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer
    Andrew J Weickhardt
    Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA
    Cancer 119:1467-77. 2013
    ..In the current review, the authors summarize the diagnostic tests available, or likely to become available, that could be used to identify patients with ALK-positive NSCLC, highlighting the pros and cons of each...
  34. pmc Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer
    Xiaoping Yang
    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
    Clin Cancer Res 19:148-57. 2013
    ..We tested DAB(389)EGF for antitumor activity in both in vitro and in vivo urinary bladder cancer models...
  35. ncbi request reprint Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner
    Thomas W Flaig
    Department of Medicine, Division of Medical Oncology, University of Colorado Denver School of Medicine, Aurora, CO 80045 0511, USA
    BJU Int 103:1729-37. 2009
    ....
  36. ncbi request reprint The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
    Ali Ziada
    UCHSC, 4200 E 9th Ave C 319, Denver, CO, USA
    Prostate 60:332-7. 2004
    ..To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC)...
  37. pmc Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
    D Ross Camidge
    University of Colorado Denver, Aurora, CO, USA
    Lancet Oncol 13:1011-9. 2012
    ..We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identified to have an ALK fusion within the first-in-man phase 1 crizotinib study...
  38. ncbi request reprint Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium
    Britta M Jacobsen
    Department of Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA
    Cancer Res 66:8274-9. 2006
    ..The transformed stroma-derived cells are tumorigenic with histopathologic features of malignancy, suggesting a new mechanism for tumor progression...
  39. pmc Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment
    D Ross Camidge
    Division of Medical Oncology and Department of Pathology, University of Colorado Denver, 1665 North Ursula Street, Aurora, CO 80045 0508, USA
    Clin Cancer Res 16:5581-90. 2010
    ..We explored the heterogeneity basis, the requirements for accurately determining ALK FISH positivity, and the effect of enriching the tested population using clinical and molecular factors...
  40. ncbi request reprint Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy
    Marileila Varella-Garcia
    Department of Medicine, Medical Oncology Division, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Oncologist 8:45-58. 2003
    ..This overview illustrates current uses and outlines potential applications for molecular cytogenetics in clinical oncology...
  41. doi request reprint Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation
    Ricardo D Coletta
    Department of Obstretrics and Gynecology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    Cancer Res 68:2204-13. 2008
    ....
  42. ncbi request reprint EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome
    Lynne T Bemis
    Department of Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, CO, USA
    Lancet Oncol 8:559-60. 2007
  43. ncbi request reprint HER2/neu expression in malignant lung tumors
    Fred R Hirsch
    Lung Cancer Program, Department of Pathology, University of Colorado Cancer Center, Denver, CO 80262, USA
    Semin Oncol 29:51-8. 2002
    ..Future studies in NSCLC need to include immunohistochemistry and fluorescence in situ hybridization analysis to determine the method of choice for evaluating clinically relevant HER2/neu-positive tumors...
  44. pmc Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions
    Ichiro Nakachi
    University of Colorado, Anschutz Medical Campus, 12700, East 19th Avenue, RC2 9th Floor, Aurora, CO 80045
    Cancer Prev Res (Phila) 7:255-65. 2014
    ..Cancer Prev Res; 7(2); 255-65. ©2013 AACR. ..
  45. pmc A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer
    Andrew Weickhardt
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    J Thorac Oncol 7:419-26. 2012
    ....
  46. ncbi request reprint Gene amplification is a mechanism of Six1 overexpression in breast cancer
    Kelly J Reichenberger
    Department of Biochemistry and Molecular Genetics, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    Cancer Res 65:2668-75. 2005
    ..These data implicate Six1 gene amplification/overrepresentation as a mechanism of Six1 mRNA overexpression in human breast cancer...
  47. ncbi request reprint Karyotypic characteristics of human uterine leiomyoma and myometrial cell lines following telomerase induction
    Marileila Varella-Garcia
    Department of Medicine, Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, 80045, USA
    Cancer Genet Cytogenet 170:71-5. 2006
    ..This phenomenon was not observed in the UtSMC cells...
  48. ncbi request reprint Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification
    Brian L Rothschild
    Department of Craniofacial Biology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado, USA
    Cancer Res 66:8017-25. 2006
    ..These data suggest that cortactin may be a valid prognostic and therapeutic marker for invasive and metastatic HNSCC and other carcinomas with 11q13 amplification...
  49. pmc Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma
    Thomas W Flaig
    Department of Medicine, University of Colorado, School of Medicine, Aurora, CO, USA
    Urology 78:863-7. 2011
    ..To examine the incidence and prognostic value of circulating tumor cells (CTCs) in urothelial cancer (UC). The detection of CTCs is prognostic in several cancer types...
  50. pmc A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins
    Stephen B Keysar
    Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine UCSOM, Aurora, CO 80045, United States
    Mol Oncol 7:776-90. 2013
    ..This model enables to prospectively test therapeutic-oriented hypotheses leading to personalized medicine...
  51. pmc Chromosomal imbalances are uncommon in chagasic megaesophagus
    Marilanda F Bellini
    UNESP, Sao Paulo State University, Department of Biology, Campus São José do Rio Preto, SP, Brazil
    BMC Gastroenterol 10:20. 2010
    ..Based on the association between CM and ESCC, we investigated whether genes frequently showing unbalanced copy numbers in ESCC were altered in CM by fluorescence in situ (FISH) technology...
  52. ncbi request reprint Molecular and cytogenetic analyses on Brazilian youths with pervasive developmental disorders
    MarcosRobertoHigino Estécio
    Laboratório de Citogenética e Biologia Molecular, Instituto de Bio ciências, Letras e Ciências Exatas UNESP Campus de São José do Rio Preto, SP, Brazil
    J Autism Dev Disord 32:35-41. 2002
    ....
  53. pmc De novo generation of white adipocytes from the myeloid lineage via mesenchymal intermediates is age, adipose depot, and gender specific
    Susan M Majka
    Charles C Gates Regenerative Medicine and Stem Cell Biology Program, Department of Pediatrics, Cardiovascular Pulmonary Research Laboratory, University of Colorado, Aurora, CO 80045, USA
    Proc Natl Acad Sci U S A 107:14781-6. 2010
    ..BMP-derived adipocytes may, therefore, account in part for adipose depot heterogeneity and detrimental changes in adipose metabolism and inflammation with aging and adiposity...